dc.contributor.author | Ozkoca, Defne | |
dc.contributor.author | SERDAROĞLU, Server | |
dc.contributor.author | UZUNÇAKMAK, Tuğba Kevser | |
dc.contributor.author | AŞKIN, Özge | |
dc.date.accessioned | 2021-03-02T15:47:57Z | |
dc.date.available | 2021-03-02T15:47:57Z | |
dc.identifier.citation | AŞKIN Ö., Ozkoca D., UZUNÇAKMAK T. K. , SERDAROĞLU S., "Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic", DERMATOLOGIC THERAPY, 2021 | |
dc.identifier.issn | 1396-0296 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_63843c34-0795-4b48-aa83-82e125617e9c | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/1824 | |
dc.identifier.uri | https://doi.org/10.1111/dth.14746 | |
dc.description.abstract | Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P < .001). Statistically significant relationships of age (P = .013) and treatment duration (P < .001) to recurrence were also found. The change in the SALT score differed between the patients on therapy and off therapy during the pandemic (P < .001). A significant negative correlation was found between the change in the SALT score and treatment duration: the spearman correlation test P = .018. We concluded that the patients may continue to the tofacitinib therapy during the rest of the COVID-19 pandemic if the benefit outweighed the risk. | |
dc.language.iso | eng | |
dc.subject | Dermatology | |
dc.subject | Health Sciences | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Dermatoloji | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | DERMATOLOJİ | |
dc.title | Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic | |
dc.type | Makale | |
dc.relation.journal | DERMATOLOGIC THERAPY | |
dc.contributor.department | İstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.contributor.firstauthorID | 2512675 | |